secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2022-12-28T23:59:59+00:00
Accession:  0001213900-22-083290
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada extends key man provisions in esmethadone license to Dec 31, 2027
-------------------------------------------------------------------------

- Amendment No. 2 extends the 'Key Man' termination-protection period from Dec 31, 2022 to Dec 31, 2027.
- Licensor may terminate license if CEO Sergio Traversa is fired without cause or his role is materially reduced.
- License covers esmethadone (REL-1017) for psychiatric use; no other terms of the license were changed.
- Extension locks in CEO-linked protections for an additional five years through 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/0001213900-22-083290-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390022083290/ea170963-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-083290

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer